Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study.

Journal of gynecologic oncology - 1 Nov 2024

Chang Yu-Wei, Kuo Hsiao-Li, Chen Tzu-Chien, Chen Jessica, Lim Ling, Wang Kung-Liahng, Chen Jen-Ruei

Abstract excerpt

OBJECTIVE: The Cancer Genome Atlas study revealed an association between copy-number high (p53 abnormal) genetic mutation and poor prognosis in endometrial cancer in 2013. This retrospective study investigated outcomes in patients with abnormal p53 expression and stage I, low-grade endometrial endometrioid carcinoma (EEC). METHODS: We enrolled women with stage I, grade 1 or 2 EEC who received comprehensive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Endometrioid
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Progression-Free Survival

Share to Taiwan

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 38576345
DOI: 10.3802/jgo.2024.35.e78
PMCID: PMC11543261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study.PMID 38576345Read ↗

p53 Abnormal (Copy Number High) Endometrioid Endometrial Carcinoma Has a Prognosis Indistinguishable From Serous Carcinoma.Semantic proximity Read ↗

Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence.Semantic proximity Read ↗

Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments.Semantic proximity Read ↗

CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.Semantic proximity Read ↗

Association of Molecular Classification with FIGO Stage and Survival Outcomes in Endometrial Cancer.Semantic proximity Read ↗

High-grade endometrial carcinomas: Morphologic spectrum and molecular classification.Semantic proximity Read ↗

The prognosis of endometrial cancers stratified with conventional risk factors and modified molecular classificationSemantic proximity Read ↗

Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification.Semantic proximity Read ↗

Impact of molecular classification on recurrence risk in endometrial cancer patients with lymph node metastasis: multicenter retrospective study.Semantic proximity Read ↗

Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.Semantic proximity Read ↗

Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.